Why this case matters
Ovarian carcinosarcoma (malignant mixed Müllerian tumor, MMMT) is an exceptionally rare ovarian malignancy, typically occurring in postmenopausal women. This report describes a 33-year-old woman diagnosed with FIGO stage IB ovarian carcinosarcoma after complete surgical staging. The case underscores the difficulty of distinguishing this tumor from more common ovarian neoplasms using imaging and tumor markers alone, emphasizing the critical role of histopathology and immunohistochemistry in establishing the diagnosis.
Following optimal cytoreductive surgery and six cycles of carboplatin-paclitaxel chemotherapy, the patient underwent germline BRCA1/2 and homologous recombination deficiency testing, both of which were negative. Despite the absence of established molecular indications, maintenance olaparib was initiated after multidisciplinary discussion and informed consent as an individualized off-label strategy. The patient has remained free of clinical, biochemical, and radiographic recurrence for approximately 46 months. The authors appropriately emphasize that this favorable outcome should not be interpreted as evidence supporting routine PARP inhibitor use in BRCA- or HRD-negative ovarian carcinosarcoma but rather as a hypothesis-generating observation that warrants further investigation.
Clinical Take-Home Message
Rare ovarian carcinosarcomas should remain in the differential diagnosis of large complex adnexal masses in younger women. Optimal cytoreductive surgery and platinum-based chemotherapy remain the cornerstone of management, while individualized targeted therapies should be considered cautiously and only within the context of multidisciplinary decision-making until stronger evidence becomes available.
Multiple Choice Question
A 33-year-old premenopausal woman is diagnosed with FIGO stage IB ovarian carcinosarcoma (malignant mixed Müllerian tumor). Germline BRCA1/2 and homologous recombination deficiency (HRD) testing are negative. Following complete cytoreductive surgery and platinum-based chemotherapy, she remains disease-free during prolonged follow-up after receiving off-label maintenance olaparib. Based on this case report, which of the following is the most appropriate conclusion?
A. PARP inhibitors should become the standard maintenance therapy for all ovarian carcinosarcomas regardless of BRCA or HRD status.
B. Ovarian carcinosarcoma is typically diagnosed preoperatively based on characteristic imaging findings.
C. Optimal cytoreductive surgery and platinum-based chemotherapy remain the cornerstone of treatment, while individualized off-label PARP inhibitor therapy in BRCA-/HRD-negative patients remains investigational.
D. Premenopausal women have a better prognosis than postmenopausal women because ovarian carcinosarcoma is biologically less aggressive in younger patients.
Correct Answer: C
Explanation
Answer C is correct. Ovarian carcinosarcoma is a rare, highly aggressive malignancy with limited evidence to guide treatment. This case demonstrates prolonged disease control after complete cytoreductive surgery, platinum-based chemotherapy, and individualized off-label maintenance olaparib despite negative BRCA and HRD testing. However, the authors emphasize that this single case should not be interpreted as evidence supporting routine PARP inhibitor use in BRCA- or HRD-negative ovarian carcinosarcoma. Rather, it is a hypothesis-generating observation that requires validation in future studies.
Journal of Medical Case Reports is the world's first international, PubMed-listed medical journal devoted to publishing case reports from all medical disciplines and will consider any original case report that expands the field of general medical knowledge, and original research relating to case reports. The journal is open access and strongly endorses the CARE guidelines for case reports, requiring authors to submit populated CARE checklists with submissions to improve transparency in reporting.